EMERGENT BIOSOLUTIONS INC. Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised
EMERGENT BIOSOLUTIONS INC. (EBS) reported Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised of $1.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Financing Activities
us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2026-06-30 was $1.40M, a 100.00% increase year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2026-03-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for the quarter ending 2025-09-30 was -$800.00K.
- EMERGENT BIOSOLUTIONS INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2025 was $0.00, a 100.00% decline from fiscal 2024.
- EMERGENT BIOSOLUTIONS INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2024 was $1.50M, a 16.67% decline from fiscal 2023.
- EMERGENT BIOSOLUTIONS INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2023 was $1.80M, a 64.00% decline from fiscal 2022.
- EMERGENT BIOSOLUTIONS INC. proceeds, issuance of shares, share-based payment arrangement, including option exercised for fiscal 2022 was $5.00M, a 68.55% decline from fiscal 2021.
| Period end | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 3 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 6 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 9 month | Proceeds, Issuance of Shares, Share-based Payment Arrangement, Including Option Exercised 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.40M 10-Q · filed 2026-08-06 | $1.40M derived: sum of 3 quarters · filed 2026-08-06 | $600.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $0.00 10-Q · filed 2026-05-01 | $0.00 derived: sum of 2 quarters · filed 2026-05-01 | -$800.00K derived: sum of 3 quarters · filed 2026-05-01 | -$100.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$800.00K derived: sum of 2 quarters · filed 2026-02-27 | -$100.00K derived: sum of 3 quarters · filed 2026-08-06 | $0.00 10-K · filed 2026-02-27 |
| 2025-09-30 | -$800.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | -$100.00K derived: sum of 2 quarters · filed 2026-08-06 | $0.00 10-Q · filed 2025-10-30 | $800.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $800.00K 10-Q · filed 2026-08-06 | $1.60M derived: sum of 3 quarters · filed 2026-08-06 | $1.60M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-01 | $900.00K derived: sum of 2 quarters · filed 2026-05-01 | $900.00K derived: sum of 3 quarters · filed 2026-05-01 | $1.60M derived: sum of 4 quarters · filed 2026-05-01 |
| 2024-12-31 | $800.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $800.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.50M derived: sum of 3 quarters · filed 2026-02-27 | $1.50M 10-K · filed 2026-02-27 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $700.00K derived: sum of 2 quarters · filed 2025-10-30 | $700.00K 10-Q · filed 2025-10-30 | $1.20M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | $700.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $700.00K 10-Q · filed 2025-08-07 | $1.20M derived: sum of 3 quarters · filed 2026-02-27 | $1.20M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | $0.00 10-Q · filed 2025-05-08 | $500.00K derived: sum of 2 quarters · filed 2026-02-27 | $500.00K derived: sum of 3 quarters · filed 2026-02-27 | $1.80M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | $500.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $500.00K derived: sum of 2 quarters · filed 2026-02-27 | $1.80M derived: sum of 3 quarters · filed 2026-02-27 | $1.80M 10-K · filed 2026-02-27 |
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $1.30M derived: sum of 2 quarters · filed 2024-11-07 | $1.30M 10-Q · filed 2024-11-07 | $3.30M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-06-30 | $1.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.30M 10-Q · filed 2024-08-07 | $3.30M derived: sum of 3 quarters · filed 2025-03-04 | $3.30M derived: sum of 4 quarters · filed 2025-03-04 |
| 2023-03-31 | $0.00 10-Q · filed 2023-05-10 | $2.00M derived: sum of 2 quarters · filed 2025-03-04 | $2.00M derived: sum of 3 quarters · filed 2025-03-04 | $4.50M derived: sum of 4 quarters · filed 2025-03-04 |
| 2022-12-31 | $2.00M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-04 | $2.00M derived: sum of 2 quarters · filed 2025-03-04 | $4.50M derived: sum of 3 quarters · filed 2025-03-04 | $5.00M 10-K · filed 2025-03-04 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-12-11 | $2.50M derived: sum of 2 quarters · filed 2023-12-11 | $3.00M 10-Q · filed 2023-12-11 | $6.40M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-06-30 | $2.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $3.00M 10-Q · filed 2023-08-09 | $6.40M derived: sum of 3 quarters · filed 2024-03-08 | $8.90M derived: sum of 4 quarters · filed 2024-03-08 |
| 2022-03-31 | $500.00K 10-Q · filed 2023-05-10 | $3.90M derived: sum of 2 quarters · filed 2024-03-08 | $6.40M derived: sum of 3 quarters · filed 2024-03-08 | $9.50M derived: sum of 4 quarters · filed 2024-03-08 |
| 2021-12-31 | $3.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-08 | $5.90M derived: sum of 2 quarters · filed 2024-03-08 | $9.00M derived: sum of 3 quarters · filed 2024-03-08 | $15.90M 10-K · filed 2024-03-08 |
| 2021-09-30 | $2.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $5.60M derived: sum of 2 quarters · filed 2022-11-09 | $12.50M 10-Q · filed 2022-11-09 | $17.50M derived: sum of 4 quarters · filed 2023-12-11 |
| 2021-06-30 | $3.10M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02 | $10.00M 10-Q · filed 2022-08-02 | $15.00M derived: sum of 3 quarters · filed 2023-12-11 | $18.50M derived: sum of 4 quarters · filed 2023-12-11 |
| 2021-03-31 | $6.90M 10-Q · filed 2022-04-29 | $11.90M derived: sum of 2 quarters · filed 2023-12-11 | $15.40M derived: sum of 3 quarters · filed 2023-12-11 | $29.40M derived: sum of 4 quarters · filed 2023-12-11 |
| 2020-12-31 | $5.00M derived: 10-K/A 12 month − 10-Q 9 month · filed 2023-12-11 | $8.50M derived: sum of 2 quarters · filed 2023-12-11 | $22.50M derived: sum of 3 quarters · filed 2023-12-11 | $31.60M 10-K/A · filed 2023-12-11 |
| 2020-09-30 | $3.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-05 | $17.50M derived: sum of 2 quarters · filed 2021-11-05 | $26.60M 10-Q · filed 2021-11-05 | |
| 2020-06-30 | $14.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-30 | $23.10M 10-Q · filed 2021-07-30 | ||
| 2020-03-31 | $9.10M 10-Q · filed 2021-04-30 | |||
| 2019-12-31 | $8.20M 10-K · filed 2022-02-25 | |||
| 2018-12-31 | $15.90M 10-K · filed 2021-02-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |